Cargando…
Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis
(1) Background: With new potential drug targets emerging, combination therapies appear attractive to treat non-alcoholic steatohepatitis (NASH) and fibrosis. Chemokine receptor CCR2/5 antagonists can improve fibrosis by reducing monocyte infiltration and altering hepatic macrophage subsets. Fibrobla...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224277/ https://www.ncbi.nlm.nih.gov/pubmed/35743140 http://dx.doi.org/10.3390/ijms23126696 |
_version_ | 1784733325765640192 |
---|---|
author | Puengel, Tobias Lefere, Sander Hundertmark, Jana Kohlhepp, Marlene Penners, Christian Van de Velde, Frederique Lapauw, Bruno Hoorens, Anne Devisscher, Lindsey Geerts, Anja Boehm, Stephanie Zhao, Qihong Krupinski, John Charles, Edgar D. Zinker, Bradley Tacke, Frank |
author_facet | Puengel, Tobias Lefere, Sander Hundertmark, Jana Kohlhepp, Marlene Penners, Christian Van de Velde, Frederique Lapauw, Bruno Hoorens, Anne Devisscher, Lindsey Geerts, Anja Boehm, Stephanie Zhao, Qihong Krupinski, John Charles, Edgar D. Zinker, Bradley Tacke, Frank |
author_sort | Puengel, Tobias |
collection | PubMed |
description | (1) Background: With new potential drug targets emerging, combination therapies appear attractive to treat non-alcoholic steatohepatitis (NASH) and fibrosis. Chemokine receptor CCR2/5 antagonists can improve fibrosis by reducing monocyte infiltration and altering hepatic macrophage subsets. Fibroblast growth factor 21 (FGF21) may improve NASH by modulating lipid and glucose metabolism. We compared effects of single drug to combination treatment as therapeutic strategies against NASH. (2) Methods: We analyzed serum samples and liver biopsies from 85 nonalcoholic fatty liver disease (NAFLD) patients. A CCR2/5 inhibitor (BMS-687681-02-020) and a pegylated FGF21 agonist (BMS-986171) were tested in male C57BL/6J mice subjected to dietary models of NASH and fibrosis (choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) up to 12 weeks; short- (2w) or long-term (6w) treatment). (3) Results: In NAFLD patients, chemokine CCL2 and FGF21 serum levels correlated with inflammatory serum markers, only CCL2 was significantly associated with advanced liver fibrosis. In rodent NASH, CCR2/5 inhibition significantly reduced circulating Ly6C+ monocytes and hepatic monocyte-derived macrophages, alongside reduced hepatic inflammation and fibrosis. FGF21 agonism decreased body weight, liver triglycerides and histological NASH activity. Combination treatment reflected aspects of both compounds upon short- and long-term application, thereby amplifying beneficial effects on all aspects of steatohepatitis and fibrosis. (4) Conclusions: CCR2/5 inhibition blocks hepatic infiltration of inflammatory monocytes, FGF21 agonism improves obesity-related metabolic disorders. Combined therapy ameliorates steatohepatitis and fibrosis more potently than single drug treatment in rodent NASH, corroborating the therapeutic potential of combining these two approaches in NASH patients. |
format | Online Article Text |
id | pubmed-9224277 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92242772022-06-24 Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis Puengel, Tobias Lefere, Sander Hundertmark, Jana Kohlhepp, Marlene Penners, Christian Van de Velde, Frederique Lapauw, Bruno Hoorens, Anne Devisscher, Lindsey Geerts, Anja Boehm, Stephanie Zhao, Qihong Krupinski, John Charles, Edgar D. Zinker, Bradley Tacke, Frank Int J Mol Sci Article (1) Background: With new potential drug targets emerging, combination therapies appear attractive to treat non-alcoholic steatohepatitis (NASH) and fibrosis. Chemokine receptor CCR2/5 antagonists can improve fibrosis by reducing monocyte infiltration and altering hepatic macrophage subsets. Fibroblast growth factor 21 (FGF21) may improve NASH by modulating lipid and glucose metabolism. We compared effects of single drug to combination treatment as therapeutic strategies against NASH. (2) Methods: We analyzed serum samples and liver biopsies from 85 nonalcoholic fatty liver disease (NAFLD) patients. A CCR2/5 inhibitor (BMS-687681-02-020) and a pegylated FGF21 agonist (BMS-986171) were tested in male C57BL/6J mice subjected to dietary models of NASH and fibrosis (choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) up to 12 weeks; short- (2w) or long-term (6w) treatment). (3) Results: In NAFLD patients, chemokine CCL2 and FGF21 serum levels correlated with inflammatory serum markers, only CCL2 was significantly associated with advanced liver fibrosis. In rodent NASH, CCR2/5 inhibition significantly reduced circulating Ly6C+ monocytes and hepatic monocyte-derived macrophages, alongside reduced hepatic inflammation and fibrosis. FGF21 agonism decreased body weight, liver triglycerides and histological NASH activity. Combination treatment reflected aspects of both compounds upon short- and long-term application, thereby amplifying beneficial effects on all aspects of steatohepatitis and fibrosis. (4) Conclusions: CCR2/5 inhibition blocks hepatic infiltration of inflammatory monocytes, FGF21 agonism improves obesity-related metabolic disorders. Combined therapy ameliorates steatohepatitis and fibrosis more potently than single drug treatment in rodent NASH, corroborating the therapeutic potential of combining these two approaches in NASH patients. MDPI 2022-06-15 /pmc/articles/PMC9224277/ /pubmed/35743140 http://dx.doi.org/10.3390/ijms23126696 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Puengel, Tobias Lefere, Sander Hundertmark, Jana Kohlhepp, Marlene Penners, Christian Van de Velde, Frederique Lapauw, Bruno Hoorens, Anne Devisscher, Lindsey Geerts, Anja Boehm, Stephanie Zhao, Qihong Krupinski, John Charles, Edgar D. Zinker, Bradley Tacke, Frank Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis |
title | Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis |
title_full | Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis |
title_fullStr | Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis |
title_full_unstemmed | Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis |
title_short | Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis |
title_sort | combined therapy with a ccr2/ccr5 antagonist and fgf21 analogue synergizes in ameliorating steatohepatitis and fibrosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224277/ https://www.ncbi.nlm.nih.gov/pubmed/35743140 http://dx.doi.org/10.3390/ijms23126696 |
work_keys_str_mv | AT puengeltobias combinedtherapywithaccr2ccr5antagonistandfgf21analoguesynergizesinamelioratingsteatohepatitisandfibrosis AT leferesander combinedtherapywithaccr2ccr5antagonistandfgf21analoguesynergizesinamelioratingsteatohepatitisandfibrosis AT hundertmarkjana combinedtherapywithaccr2ccr5antagonistandfgf21analoguesynergizesinamelioratingsteatohepatitisandfibrosis AT kohlheppmarlene combinedtherapywithaccr2ccr5antagonistandfgf21analoguesynergizesinamelioratingsteatohepatitisandfibrosis AT pennerschristian combinedtherapywithaccr2ccr5antagonistandfgf21analoguesynergizesinamelioratingsteatohepatitisandfibrosis AT vandeveldefrederique combinedtherapywithaccr2ccr5antagonistandfgf21analoguesynergizesinamelioratingsteatohepatitisandfibrosis AT lapauwbruno combinedtherapywithaccr2ccr5antagonistandfgf21analoguesynergizesinamelioratingsteatohepatitisandfibrosis AT hoorensanne combinedtherapywithaccr2ccr5antagonistandfgf21analoguesynergizesinamelioratingsteatohepatitisandfibrosis AT devisscherlindsey combinedtherapywithaccr2ccr5antagonistandfgf21analoguesynergizesinamelioratingsteatohepatitisandfibrosis AT geertsanja combinedtherapywithaccr2ccr5antagonistandfgf21analoguesynergizesinamelioratingsteatohepatitisandfibrosis AT boehmstephanie combinedtherapywithaccr2ccr5antagonistandfgf21analoguesynergizesinamelioratingsteatohepatitisandfibrosis AT zhaoqihong combinedtherapywithaccr2ccr5antagonistandfgf21analoguesynergizesinamelioratingsteatohepatitisandfibrosis AT krupinskijohn combinedtherapywithaccr2ccr5antagonistandfgf21analoguesynergizesinamelioratingsteatohepatitisandfibrosis AT charlesedgard combinedtherapywithaccr2ccr5antagonistandfgf21analoguesynergizesinamelioratingsteatohepatitisandfibrosis AT zinkerbradley combinedtherapywithaccr2ccr5antagonistandfgf21analoguesynergizesinamelioratingsteatohepatitisandfibrosis AT tackefrank combinedtherapywithaccr2ccr5antagonistandfgf21analoguesynergizesinamelioratingsteatohepatitisandfibrosis |